ASCO, SITC release recommendations for reporting of immuno-oncology clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ASCO and the Society for Immunotherapy of Cancer released a joint statement with twelve clinical trial reporting recommendations that address the unique efficacy, toxicity, and combination/sequencing aspects of immuno-oncology treatments.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login